Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...

Early use of mycophenolate mofetil in at-risk patients with SLE reduced the risk of severe flare, potentially delaying lupus nephritis. Early application of mycophenolate mofetil may reduce the ...

Mycophenolate mofetil (MMF) is an immunosuppressant prodrug that is converted in vivo to mycophenolic acid, which exerts its effects chiefly by inhibiting the de novo synthesis of guanine nucleotides.

Researchers conducted a retrospective analysis of 1435 patients with limited cutaneous SSc from the Italian SPRING registry to assess the purpose of starting mycophenolate mofetil treatment and its ...

In patients with systemic sclerosis-related interstitial lung disease (SSc-ILD), pirfenidone plus mycophenolate mofetil combination therapy vs placebo plus mycophenolate mofetil led to no significant ...

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study To determine whether sirolimus (SIR) and cyclosporine ...